Revive Therapeutics
  • Home
  • About
    • Management Team
    • Advisory Clinical Team
    • Board of Directors
  • Pipeline
    • Infectious Diseases
    • Intellectual Property
  • Investor
  • News
  • Contact
Select Page

Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin

by rvvadmin | Nov 11, 2020 | 2020

TORONTO, Nov. 11, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on its...

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

by rvvadmin | Oct 26, 2020 | 2020

TORONTO, Oct. 26, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on...

Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

by rvvadmin | Oct 20, 2020 | 2020

Expanding research and development of naturally-derived psilocybin for future FDA IND-enabling and clinical studies   TORONTO, Oct. 20, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused...

Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

by rvvadmin | Sep 29, 2020 | 2020

TORONTO, Sept. 29, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on...

Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

by rvvadmin | Sep 21, 2020 | 2020

TORONTO, Sept. 21, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a corporate...

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

by rvvadmin | Sep 16, 2020 | 2020

TORONTO, Sept. 16, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the...
« Older Entries
Next Entries »

NEWS

2022

2021

2020

2019

Click Here for more news.
(Forwards to SEDAR website)

Privacy Policy

Disclaimer

  • Facebook
  • X
  • Instagram
© COPYRIGHT 2025. Revive Therapeutics Ltd. ALL RIGHTS RESERVED.